VAN-ZOLMITRIPTAN TABLET
Valsts: Kanāda
Valoda: angļu
Klimata pārmaiņas: Health Canada
Produkta apraksts
(SPC)
09-04-2015
Daži šī produkta dokumenti pašlaik nav pieejami. Varat nosūtīt pieprasījumu mūsu klientu apkalpošanas dienestam, un mēs jums paziņosim, tiklīdz mēs tos varēsim iegūt.
Nosūtīt pieprasījumu.
Nosūtīt pieprasījumu.
Aktīvā sastāvdaļa:
ZOLMITRIPTAN
Pieejams no:
VANC PHARMACEUTICALS INC
ATĶ kods:
N02CC03
SNN (starptautisko nepatentēto nosaukumu):
ZOLMITRIPTAN
Deva:
2.5MG
Zāļu forma:
TABLET
Kompozīcija:
ZOLMITRIPTAN 2.5MG
Ievadīšanas:
ORAL
Vienības iepakojumā:
100
Receptes veids:
Prescription
Ārstniecības joma:
SELECTIVE SEROTONIN AGONISTS
Produktu pārskats:
Active ingredient group (AIG) number: 0134381001; AHFS:
Autorizācija statuss:
CANCELLED PRE MARKET
Autorizācija datums:
2019-07-31
Produkta apraksts
Page | 1
PRODUCT MONOGRAPH
PR
VAN-ZOLMITRIPTAN
ZOLMITRIPTAN TABLETS
2.5 MG
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
MANUFACTURER AND DISTRIBUTOR:
Vanc Pharmaceuticals Inc.
Date of Preparation: March 25, 2015
Unit-210, 2639 Viking Way
Richmond, BC V6V 3B7
www.vancpharm.com
Control# 182335
Page | 2
TABLE OF CONTENTS
PRODUCT MONOGRAPH
......................................................................................................
1
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
5
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
17
DOSAGE AND ADMINISTRATION
................................................................................
19
OVERDOSAGE
..................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 20
STORAGE AND STABILITY
............................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
24
PHARMACEUTICAL INFORMATIO
Izlasiet visu dokumentu
